Preoperative Prediction of Lymph Node Status by Circulating Mir‐18b and Mir‐20a During Chemoradiotherapy in Patients with Rectal Cancer

Azizian, Azadeh; Krämer, Frank; Jo, Peter; Wolff, Hendrik A.; Beißbarth, Tim; Skarupke, R; Bernhardt, Markus; Grade, Marian; Ghadimi, B. Michael; Gaedcke, Jochen

doi:10.1007/s00268-015-3083-8

Cited by 28 publications

(23 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…miR-20a is a member of the miR-17-92 cluster (including miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-92a-1), which is commonly upregulated in malignant cancer and involved in carcinogenesis as the classical oncogene (16). Previous studies have reported upregulated expression levels of circulating miR-20a in malignant neoplasms, such as non-small cell lung cancer (NSCLC), and in cervical, hepatoma, colorectal and prostate cancers (17)(18)(19)(20)(21)(22). However, the association between the expression level of miR-20a and GC is rarely reported.…”

Section: Discussionmentioning

confidence: 99%

Serum miR-20a is a promising biomarker for gastric cancer

Yang

Zeng

et al. 2017

Biomedical Reports

View full text Add to dashboard Cite

Gastric cancer (GC) is a common type of cancer, particularly in China. Numerous studies have demonstrated that circulating microRNAs (miRNAs) have potential applications as noninvasive biomarkers for cancer diagnosis and prognosis. Microarray-based serum miRNA profiling was performed on the serum of 12 paired pre- and post-operative GC patients to screen differentially expressed serum miRNAs. Twelve different serum miRNAs between pre- and post-operative GC patients were identified. Those miRNAs were verified by real-time quantitative polymerase chain reaction in 110 paired pre- and post-operative serum samples from 55 GC patients. miR-20a was confirmed and demonstrated potential as a GC-associated biomarker. Furthermore, the levels of serum miR-20a were significantly different between GC, nasopharyngeal cancer, colorectal carcinoma, breast cancer and non-cancerous controls. In addition, it was found that serum miR-20a levels correlated with age, tumor stage, differentiated degree and lymph node metastasis in GC. Survival analysis indicated that GC patients with elevated levels of serum miR-20a had poor survival. Thus, serum miR-20a may serve as a molecular marker for diagnosis, evaluating therapeutic efficacy and prognosis, as well as monitoring recurrence in GC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum miR-20a is a promising biomarker for gastric cancer

Yang

Zeng

et al. 2017

Biomedical Reports

View full text Add to dashboard Cite

show abstract

“…Upregulation of miR-17-92 in tumors has a correlation with a higher risk of tumor relapse. Azizian et al [94] also found that downregulated miR-18a and miR-20a in plasma were associated with negative lymph nodes after surgery. However, a study from the Czech Republic showed that miR-17-3p and miR-92a in serum had no significant differences between colorectal cancer and health controls [95].…”

Section: Colorectal Cancermentioning

confidence: 94%

Current Advancement of the miR-17-92 Cluster in Gastrointestinal Cancers

Liu

Chen

Sun

et al. 2019

IGH

View full text Add to dashboard Cite

Gastrointestinal (GI) cancers, especially including esophageal, gastric and colorectal cancer, are common types of cancer with high morbidity and mortality worldwide. Despite great advances having been made for these cancers, current treatments including surgery, Radiotherapy (RT) and Chemotherapy (CT) are still far from satisfactory as these cancers are usually discovered in advanced stages that are associated with short longevity and poor outcomes. MicroRNAs (miRNAs) are short noncoding strands of RNA that regulate gene expression, affecting proliferation, development, differentiation, apoptosis, metabolism and Epithelial-mesenchymal Transition (EMT). The miR-17-92 cluster was detected as “oncomir-1”, which is involved in the onset and progression of numerous human cancers. This review presents the recent developments in knowledge about miR-17-92 clusters for diagnosing and treating GI cancers based on genetic functions, biological phenotypes, related mechanisms, biomarkers and therapeutic perspectives, which could provide a wider horizon for future use.

show abstract

“…Preoperative CRT blood circulating miR-20a can be used as a marker to indicate lymph node status of patients with locally advanced rectal cancer following neoadjuvant CRT. Additionally, the differential regulation of miR-20a before and after radiotherapy and chemotherapy, in patients with rectal cancer, may be used as a marker for monitoring tumor response before and after radiotherapy and chemotherapy (113)(114)(115).…”

Section: Mir-20a May Be Used As a Monitoring Indicator During Chemothmentioning

confidence: 99%

“…Chemotherapy is a widely used treatment in patients with CRC, however resistance can occur and the mechanisms behind this are undetermined. miR-20a has been indicated to be an effective indicator in monitoring response to treatment (112)(113)(114)(115)121). Furthermore, carcinoembryonic antigen (CEA) is a common tumor marker in gastrointestinal cancer, but its specificity and sensitivity are low.…”

Section: Conclusion and Prospectsmentioning

confidence: 99%

Function and mechanisms of microRNA‑20a in colorectal cancer (Review)

et al. 2020

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the third most common malignancy and the second leading cause of cancer-associated mortality worldwide. CRC currently has no specific biomarkers to promote its diagnosis and treatment and the underlying mechanisms regulating its pathogenesis have not yet been determined. MicroRNAs (miRs) are small, non-coding RNAs that exhibit regulatory functions and have been demonstrated to serve a crucial role in the post-transcriptional regulatory processes of gene expression that is associated with cell physiology and disease progression. Recently, abnormal miR-20a expression has been identified in a number of cancers types and this has become a novel focus within cancer research. High levels of miR-20a expression have been identified in CRC tissues, serum and plasma. In a recent study, miR-20a was indicated to be present in feces and to exhibit a high sensitivity to CRC. Therefore, miR-20a may be used as a marker for CRC and an indicator that can prevent the invasive examination of patients with this disease. Changes in the expression of miR-20a during chemotherapy can be used as a biomarker for monitoring resistance to treatment. In conclusion, miR-20a exhibits the potential for clinical application as a novel diagnostic biomarker and therapeutic target for use in patients with CRC. The present study focused on the role and mechanisms of miR-20a in CRC. Contents 1. Introduction 2. microRNA-20a overview 3. The mechanism of miR-20a in CRC 4. miR-20a can be used as a diagnostic marker in CRC 5. miR-20a may be used as a monitoring indicator during chemotherapy 6. Conclusion and prospects

show abstract

Preoperative Prediction of Lymph Node Status by Circulating Mir‐18b and Mir‐20a During Chemoradiotherapy in Patients with Rectal Cancer

Cited by 28 publications

References 35 publications

Serum miR-20a is a promising biomarker for gastric cancer

Serum miR-20a is a promising biomarker for gastric cancer

Current Advancement of the miR-17-92 Cluster in Gastrointestinal Cancers

Function and mechanisms of microRNA‑20a in colorectal cancer (Review)

Contact Info

Product

Resources

About